TD Private Client Wealth LLC Has $53,000 Stock Position in Insulet Co. (NASDAQ:PODD)

TD Private Client Wealth LLC lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 32.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 228 shares of the medical instruments supplier’s stock after purchasing an additional 56 shares during the quarter. TD Private Client Wealth LLC’s holdings in Insulet were worth $53,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Insulet by 3.4% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 36,054 shares of the medical instruments supplier’s stock worth $8,393,000 after purchasing an additional 1,189 shares in the last quarter. Toronto Dominion Bank grew its holdings in shares of Insulet by 15.3% during the 3rd quarter. Toronto Dominion Bank now owns 23,502 shares of the medical instruments supplier’s stock worth $5,470,000 after purchasing an additional 3,117 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in Insulet by 144.5% in the third quarter. Coldstream Capital Management Inc. now owns 2,893 shares of the medical instruments supplier’s stock valued at $714,000 after buying an additional 1,710 shares in the last quarter. Geode Capital Management LLC boosted its stake in Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after buying an additional 22,850 shares in the last quarter. Finally, M&T Bank Corp boosted its stake in Insulet by 1.8% in the third quarter. M&T Bank Corp now owns 9,061 shares of the medical instruments supplier’s stock valued at $2,108,000 after buying an additional 162 shares in the last quarter.

Analysts Set New Price Targets

Several analysts recently weighed in on PODD shares. Sanford C. Bernstein started coverage on Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Wells Fargo & Company raised their price objective on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group raised their price objective on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Finally, Citigroup raised their price objective on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $267.44.

Insulet Price Performance

Shares of PODD opened at $265.50 on Tuesday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $18.62 billion, a price-to-earnings ratio of 45.46, a price-to-earnings-growth ratio of 4.12 and a beta of 1.21. The business has a 50-day moving average of $252.13 and a 200-day moving average of $221.28.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.